|
1
|
Deng X, Cao Y, Liu Y, Li F, Sambandam K,
Rajaraman S, Perkins AS, Fields AP, Hellmich MR, Townsend CM Jr, et
al: Overexpression of Evi-1 oncoprotein represses TGF-β signaling
in colorectal cancer. Mol Carcinog. 52:255–264. 2013.PubMed/NCBI
|
|
2
|
Potter JD: Colorectal cancer: molecules
and populations. J Natl Cancer Inst. 91:916–932. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Deschoolmeester V, Baay M, Specenier P,
Lardon F and Vermorken JB: A review of the most promising
biomarkers in colorectal cancer: one step closer to targeted
therapy. Oncologist. 15:699–731. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kotzev I, Mirchev M, Manevska B, Ivanova I
and Kaneva M: Risk and protective factors for development of
colorectal polyps and cancer (Bulgarian experience).
Hepatogastroenterology. 55:381–387. 2008.PubMed/NCBI
|
|
5
|
Domínguez-Ayala M, Díez-Vallejo J and
Comas-Fuentes A: Missed opportunities in early diagnosis of
symptomatic colorectal cancer. Rev Esp Enferm Dig. 104:343–349.
2012.PubMed/NCBI
|
|
6
|
Jass JR: Colorectal cancer: a multipathway
disease. Crit Rev Oncog. 12:273–287. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fearon ER: Molecular genetics of
colorectal cancer. Annu Rev Pathol. 6:479–507. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Posner MR: Paradigm shift in the treatment
of head and neck cancer: the role of neoadjuvant chemotherapy.
Oncologist. 10(Suppl 3): 11–19. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Simoglou C, Gymnopoulou E, Simoglou L,
Gymnopoulou M, Nikolaou K and Gymnopoulos D: Surgery for colorectal
cancer in the small town of Komotini. J Multidiscip Healthc.
5:273–276. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu Y, Zhang H, Xiong X, Cao Y, Han Y and
Xi Z: Inhibitory effect of tissue transglutaminase (tTG) antisense
oligodeoxynucleotides on tTG expression in cultured bovine
trabecular meshwork cells. J Huazhong Univ Sci Technolog Med Sci.
25:729–731. 2005. View Article : Google Scholar
|
|
11
|
van Hazel GA, Pavlakis N, Goldstein D,
Olver IN, Tapner MJ, Price D, Bower GD, Briggs GM, Rossleigh MA,
Taylor DJ and George J: Treatment of fluorouracil-refractory
patients with liver metastases from colorectal cancer by using
yttrium-90 resin microspheres plus concomitant systemic irinotecan
chemotherapy. J Clin Oncol. 27:4089–4095. 2009.
|
|
12
|
Gerber DE: Targeted therapies: a new
generation of cancer treatments. Am Fam Physician. 77:311–319.
2008.PubMed/NCBI
|
|
13
|
Dehmer GJ, Douglas JS Jr, Abizaid A, et
al: SCAI/ACCF/HRS/ESC/SOLACI/APSIC statement on the use of live
case demonstrations at cardiology meetings: assessments of the past
and standards for the future. Heart Rhythm. 7:1522–1535. 2010.
View Article : Google Scholar
|
|
14
|
Liu HG and Huang HX: Overview
pharmacokinetic about traditional Chinese medicine in recent 10
years. Zhongguo Zhong Yao Za Zhi. 32:2346–2348. 2007.(In
Chinese).
|
|
15
|
Honkanen RE: Cantharidin, another natural
toxin that inhibits the activity of serine/threonine protein
phosphatases types 1 and 2A. FEBS Lett. 330:283–286. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Deng LP, Dong J, Cai H and Wang W:
Cantharidin as an antitumor agent: a retrospective review. Curr Med
Chem. 20:159–166. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang YP, Ni CH, Lu CC, et al:
Suppressions of migration and invasion by cantharidin in TSGH-8301
human bladder carcinoma cells through the inhibitions of matrix
metalloproteinase-2/-9 signaling. Evid Based Complement Alternat
Med. 2013:1902812013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhan YP, Huang XE, Cao J, et al: Clinical
study on safety and efficacy of Qinin® (cantharidin
sodium) injection combined with chemotherapy in treating patients
with gastric cancer. Asian Pac J Cancer Prev. 13:4773–4776.
2012.PubMed/NCBI
|
|
19
|
Kim YM, Ku MJ, Son YJ, Yun JM, Kim SH and
Lee SY: Anti-metastatic effect of cantharidin in A549 human lung
cancer cells. Arch Pharm Res. 36:479–484. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yeh CH, Yang YY, Huang YF, Chow KC and
Chen MF: Induction of apoptosis in human Hep3B hepatoma cells by
norcantharidin through a p53 independent pathway via TRAIL/DR5
signal transduction. Chin J Integr Med. 18:676–682. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Agnihotri N, Kumar S and Mehta K: Tissue
transglutaminase as a central mediator in inflammation-induced
progression of breast cancer. Breast Cancer Res. 15:2022013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yakubov B, Chelladurai B, Schmitt J,
Emerson R, Turchi JJ and Matei D: Extracellular tissue
transglutaminase activates noncanonical NF-κB signaling and
promotes metastasis in ovarian cancer. Neoplasia. 15:609–619.
2013.PubMed/NCBI
|
|
23
|
Caffarel MM, Chattopadhyay A, Araujo AM,
Bauer J, Scarpini CG and Coleman N: Tissue transglutaminase
mediates the pro-malignant effects of oncostatin M receptor
over-expression in cervical squamous cell carcinoma. J Pathol.
231:168–179. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Z, Perez M, Caja S, Melino G, Johnson
TS, Lindfors K and Griffin M: A novel extracellular role for tissue
transglutaminase in matrix-bound VEGF-mediated angiogenesis. Cell
Death Dis. 4:e8082013. View Article : Google Scholar : PubMed/NCBI
|
